Recent Finacing
Recent Raise
Amydis develops proprietary small-molecule retinal tracers that bind misfolded proteins (amyloid‑β, α‑synuclein, TDP‑43) and builds multi‑omics retinal–blood–genomic datasets and imaging tools for noninvasive neurodegenerative biomarker detection.
